Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade.
Rwandamuriye FX, Wang T, Zhang H, Elaskalani O, Kuster J, Ye X, Vitali B, Schreurs J, Orozco Morales ML, Norret M, Evans CW, Zemek RM, Iyer KS, Lesterhuis WJ, Wylie B.
Rwandamuriye FX, et al. Among authors: elaskalani o.
Oncoimmunology. 2024 Aug 22;13(1):2395067. doi: 10.1080/2162402X.2024.2395067. eCollection 2024.
Oncoimmunology. 2024.
PMID: 39188754
Free PMC article.